(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2021.
“This has been an important year for RAPT as we advance the development of RPT193 in atopic dermatitis and FLX475 in cancer,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics.“In the third quarter, we presented additional incremental data for RPT193 at two separate dermatology meetings, allowing us to share our early positive data in atopic dermatitis with key members of the medical community. We are well positioned to advance RPT193 into Phase 2 clinical trials in atopic dermatitis and asthma in 2022. In addition, we have begun to focus development of FLX475 in key indications showing early promise, including EBV+ lymphoma, nasopharyngeal cancer and head and neck cancer. Our goal is to report data from ongoing cohorts in the Phase 1/2 trial for FLX475 at a medical meeting in 2022.”
Financial Results for the Third Quarter Ended September 30, 2021
Third Quarter ended September 30, 2021
Net loss for the third quarter of 2021 was $18.7 million, compared to $14.6 million for the third quarter of 2020.
Research and development expenses for the third quarter of 2021 were $15.7 million, compared to $12.9 million for the same period in 2020. This increase was primarily due to increased clinical trial costs for FLX475 and RPT193 and increases in stock-based compensation, personnel costs and facilities costs.
General and administrative expenses for the third quarter of 2021 were $3.8 million, compared to $3.2 million for the same period of 2020. The increase was primarily due to increases in stock-based compensation expense, insurance expense, personnel costs and facilities costs.
Nine Months Ended September 30, 2021
Net loss for the nine months ended September 30, 2021 was $51.3 million, compared to $40.2 million for the same period in 2020.
Research and development expenses for the nine months ended September 30, 2021 were $42.7 million, compared to $34.6 million for the same period in 2020. The increase was primarily due to increases in costs related to the clinical trials of FLX475 and RPT193, as well as increases in stock-based compensation, personnel expenses, facilities costs and laboratory supplies spend.
General and administrative expenses for the nine months ended September 30, 2021 were $11.5 million, compared to $9.3 million for the same period of 2020. The increase in general and administrative expenses was primarily due to increases in stock-based compensation expense, insurance expense and personnel costs.
As of September 30, 2021, the Company had cash and cash equivalents and marketable securities of $210.8 million.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the progress of RAPT's inflammation and oncology programs and RAPT's intended plans for the clinical development of RPT193 and FLX475. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.
RAPT Media Contact:
Aljanae Reynolds
RAPT Investor Contact:
Sylvia Wheeler
| RAPT THERAPEUTICS INC. |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| (In thousands, except share per share data) |
| (Unaudited) |
| | | | | | | | | |
| | | Three Months Ended | | Nine Months Ended |
| | | September 30, | | September 30, |
| | | | 2021 | | | | 2020 | | | | 2021 | | | | 2020 | |
| Revenue | | $ | 966 | | | $ | 1,528 | | | $ | 3,057 | | | $ | 3,740 | |
| Operating expenses: | | | | | | | | |
| Research and development | | | 15,725 | | | | 12,912 | | | | 42,686 | | | | 34,581 | |
| General and administrative | | | 3,774 | | | | 3,197 | | | | 11,546 | | | | 9,288 | |
| Total operating expenses | | | 19,499 | | | | 16,109 | | | | 54,232 | | | | 43,869 | |
| Loss from operations | | | (18,533 | ) | | | (14,581 | ) | | | (51,175 | ) | | | (40,129 | ) |
| Other income (expense), net | | | (118 | ) | | | 237 | | | | (100 | ) | | | 763 | |
| Net loss before taxes | | | (18,651 | ) | | | (14,344 | ) | | | (51,275 | ) | | | (39,366 | ) |
| Provision for income taxes | | | — | | | | 287 | | | | — | | | | 791 | |
| Net loss | | $ | (18,651 | ) | | $ | (14,631 | ) | | $ | (51,275 | ) | | $ | (40,157 | ) |
| Other comprehensive income (loss): | | | | | | | | |
| Foreign currency translation adjustment | | | 173 | | | | (70 | ) | | | 281 | | | | (65 | ) |
| Unrealized gain (loss) on marketable securities | | | 9 | | | | (33 | ) | | | (59 | ) | | | 119 | |
| Total comprehensive loss | | $ | (18,469 | ) | | $ | (14,734 | ) | | $ | (51,053 | ) | | $ | (40,103 | ) |
| Net loss per share, basic and diluted | | $ | (0.63 | ) | | $ | (0.60 | ) | | $ | (1.92 | ) | | $ | (1.67 | ) |
| Weighted average number of shares used in computing net loss per share, basic and diluted | | | 29,491,857 | | | | 24,449,115 | | | | 26,663,209 | | | | 23,989,926 | |
| | | | | | | | | |
| RAPT THERAPEUTICS, INC. |
| CONDENSED CONSOLIDATED BALANCE SHEETS |
| (In thousands) |
| | | | | |
| | | September 30, | | December 31, |
| | | 2021 | | 2020 |
| Assets | | (Unaudited) | | (1 ) |
| Current assets: | | | | |
| Cash and cash equivalents | | $ | 59,999 | | | $ | 24,918 | |
| Marketable securities | | | 150,787 | | | | 86,592 | |
| Prepaid expenses and other current assets | | | 3,709 | | | | 4,088 | |
| Total current assets | | | 214,495 | | | | 115,598 | |
| Property and equipment, net | | | 2,578 | | | | 2,982 | |
| Other assets | | | 389 | | | | 389 | |
| Total assets | | $ | 217,462 | | | $ | 118,969 | |
| Liabilities and stockholders' equity | | | | |
| Current liabilities: | | | | |
| Accounts payable | | $ | 4,017 | | | $ | 2,383 | |
| Accrued expenses | | | 6,845 | | | | 4,935 | |
| Deferred revenue, current | | | 1,538 | | | | 4,096 | |
| Other current liabilities | | | 295 | | | | 328 | |
| Total current liabilities | | | 12,695 | | | | 11,742 | |
| Deferred rent, net of current portion | | | 2,149 | | | | 2,185 | |
| Deferred revenue, non-current | | | 745 | | | | 863 | |
| Total liabilities | | | 15,589 | | | | 14,790 | |
| Commitments | | | | |
| Stockholders' equity: | | | | |
| Preferred stock | | | — | | | | — | |
| Common stock | | | 3 | | | | 2 | |
| Additional paid-in capital | | | 467,942 | | | | 319,196 | |
| Accumulated other comprehensive income (loss) | | | 45 | | | | (177 | ) |
| Accumulated deficit | | | (266,117 | ) | | | (214,842 | ) |
| Total stockholders' equity | | | 201,873 | | | | 104,179 | |
| Total liabilities and stockholders' equity | | $ | 217,462 | | | $ | 118,969 | |
| | | | | |
| (1) The condensed consolidated balance sheet for December 31, 2020 has been derived from audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 |
MENAFN10112021004107003653ID1103145858
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.